Security and Effectiveness Assessment of Locking Systems in Ventriculostomy for Traumatic Brain Injury
Launched by MEDITECH FOUNDATION · Jan 7, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different methods of treating patients with severe traumatic brain injuries (TBI) who have high pressure inside their skulls, a condition known as increased intracranial pressure (ICP). The standard treatment involves placing a small tube, called a catheter, into the brain to drain excess fluid and relieve pressure. The new approach being tested adds a special locking device to this catheter to help keep it securely in place, which may reduce complications like the catheter moving out of position or the need for more surgeries. The goal of the study is to see if this locking device improves recovery and reduces complications compared to the standard method.
To participate in this trial, patients must be between 18 and 70 years old and arrive at the emergency room within 24 hours after their injury. They should have specific abnormalities on their brain scans that indicate serious injury. Participants will either receive the standard treatment or the one with the locking device, and their recovery will be monitored during their hospital stay and through follow-up calls over the next year. This research aims to enhance treatment safety and effectiveness for TBI patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. TBI patients arriving at the emergency room in the first 24 hours following trauma.
- • 2. Abnormal Computed Tomography (CT), with a primary injury including any epidural, intracerebral, or subdural collection with a midline shift \>3 mm and any basal cistern compression with at least 2 abnormal findings in the initial evaluation at the emergency room (including optic nerve ultrasound \> 6mm on the same side of the CT´s primary injury and/or an abnormal pupillometry with a reduced Maximum Contraction Velocity (MCV) in the pupil of the same side of the CT´s primary injury, or/and a Trans-Cranial Doppler (TCD) with Pulsatility Index (PI) \> 1.3 and/or Medium Cerebral Artery - Diastolic Velocity (MCA-DV) \< 20cm/seg on the same side of the CT´s primary injury or/and an Intracranial Pressure Wave Form (ICPWF)2 \> ICPWF1 waveform pattern on the same side of the CT´s primary injury).
- • 3. Age 18 to 70 years old.
- • 4. Patients with or without polytrauma with survival expectancy \>24 hours.
- • 5. Ventriculostomy surgical procedures less than 24 hours after the trauma.
- Exclusion Criteria:
- • 1. TBI patients arriving at the emergency room after 24 hours following trauma.
- • 2. Normal CT scan at the emergency room.
- • 3. Abnormal CT scan at the emergency room with any primary injury and midline shift less than 3mm or without basal cistern compression and with normal values in at least two different modalities of assessing ICCS (pupillometry, optic nerve sheath ultrasound, transcranial Doppler, and/or non-invasive ICP waveform analyzer).
- • 4. Age less than 18 or more than 70 years old.
- • 5. Polytrauma or massive brain injury with survival expectancy \< 24 hours.
- • 6. Ventriculostomy surgical procedures performed \> 24 hours after the trauma.
About Meditech Foundation
Meditech Foundation is a leading clinical trial sponsor dedicated to advancing medical research and innovation in healthcare. With a strong focus on improving patient outcomes, the foundation collaborates with healthcare professionals, academic institutions, and industry partners to design and conduct rigorous clinical studies. Committed to ethical standards and patient safety, Meditech Foundation leverages cutting-edge technologies and methodologies to facilitate the development of new therapies and medical devices. Through its comprehensive approach to clinical trials, the foundation aims to bridge the gap between research and real-world application, ultimately enhancing the quality of care delivered to patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Andres M Rubiano, MD
Principal Investigator
Meditech Foundation
Luigi V Berra, MD
Principal Investigator
La Sapienza University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported